Rochester Institute of Technology Ultrasound Program Wins Continuing Accreditation

Rochester Institute of Technology: The diagnostic medical sonography program at Rochester Institute of Technology was awarded continuing accreditation in compliance with national standards and guidelines established by the profession.

The Commission on Accreditation of Allied Health Education Programs led the comprehensive evaluation of the program in conjunction with a peer review conducted by the Joint Review Committee on Education in Diagnostic Medical Sonography. Accreditation verifies the high caliber of RIT’s sonography/ultrasound program in specialty areas of abdominal-extended, cardiac, and obstetrics and gynecology education and ensures the education of qualified sonographers.

RIT offers diagnostic medical sonography (ultrasound) BS/certificate and echocardiography (cardiac ultrasound) certificate programs within the College of Health Sciences and Technology. Ultrasound education at RIT has expanded and advanced under the leadership of professor and director Hamad Ghazle and his team.

“Accreditation is not only about assessing programmatic performance, but also about transformative and strategic plans that will improve the quality and clarity of experiences of all involved and prepare individuals for a lifetime of learning and leadership,” Ghazle said.

His team works together to ensure a high level of excellence in ultrasound education. “It is a commitment and a responsibility we take seriously,” Ghazle said. “Our success is mirrored in the success of our graduates, who better the community with their skill and knowledge. Our continued accreditation keeps standards high for everyone involved—RIT, our students, our graduates and the community in which they work, and most of all, for the patients they serve.”

The Commission on Accreditation of Allied Health Education Programs evaluates programs that prepare health professionals in a variety of disciplines.

National standards for diagnostic medical sonography programs are established by the commission and joint review committee along with the American College of Cardiology Foundation, American College of Radiology, American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Radiologic Technologists, International Contrast Ultrasound Society, Society of Diagnostic Medical Sonography, and the Society for Vascular Ultrasound.

The accreditation process repeats every five years and includes regular monitoring of program compliance. RIT’s diagnostic medical sonography program has until 2027 to complete its next evaluation and site visit.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy